ERS临床实践指南:经鼻高流量氧疗在急性呼吸衰竭中的应用
欧洲呼吸学会工作组采用GRADE方法,针对成人急性呼吸衰竭患者,比较经鼻高流量氧疗(HFNC)与常规氧疗(COT)及无创通气(NIV)的使用场景,形成8条条件性推荐。指南认为HFNC是急性呼吸衰竭患者的有价值干预措施,可辅助临床医生在不同急性场景中选择最合适的无创呼吸支持方式。
要点
- 低氧性急性呼吸衰竭:HFNC优于COT和NIV。
- NIV间歇期:HFNC优于COT。
- 拔管失败高风险:首选NIV,除非有禁忌。
核心结论
- HFNC是成人急性呼吸衰竭的有价值干预措施。
- 形成的8条推荐均为条件性推荐,可辅助临床选择无创呼吸支持方式。
研究设计与样本
- 欧洲呼吸学会工作组由肺病学和重症医学专家及方法学家组成。
- 采用GRADE方法总结证据并制定临床推荐。
主要发现
- 低氧性急性呼吸衰竭:建议HFNC优于COT。
- 低氧性急性呼吸衰竭:建议HFNC优于NIV。
- NIV间歇期:建议HFNC优于COT。
- 术后低风险肺部并发症:建议HFNC或COT均可。
- 术后高风险肺部并发症:建议HFNC或NIV均可。
关键数值与推荐
- 共形成8条条件性推荐。
临床怎么用
- 根据急性呼吸衰竭类型和临床场景选择HFNC、COT或NIV。
- 低氧性急性呼吸衰竭优先考虑HFNC而非COT或NIV。
- 拔管失败高风险患者优先选择NIV而非HFNC。
- COPD合并高碳酸性急性呼吸衰竭患者应先尝试NIV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-flow nasal cannula (HFNC) has become a frequently used noninvasive form of respiratory support in acute settings; however, evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF). MATERIALS AND METHODOLOGY: The European Respiratory Society task force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The task force used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and noninvasive ventilation (NIV) for the management of adults in acute settings with ARF. RESULTS: The task force developed eight conditional recommendations, suggesting the use of 1) HFNC over COT in hypoxaemic ARF; 2) HFNC over NIV in hypoxaemic ARF; 3) HFNC over COT during breaks from NIV; 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications; 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications; 6) HFNC over COT in nonsurgical patients at low risk of extubation failure; 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV; and 8) trialling NIV prior to use of HFNC in patients with COPD and hypercapnic ARF. CONCLUSIONS: HFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of noninvasive respiratory support to provide to patients in different acute settings.
引用
- Oczkowski S, Ergan B, Bos L, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J. 2022. PMID: 34649974. doi:10.1183/13993003.01574-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。